Optimized experimental design for the estimation of enzyme kinetic parameters: An experimental evaluation

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2273-2279

  Sjögren, Erik ^a   Svanberg, Petter ^b   Kanebratt, Kajsa P ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AZ01; AZ02; AZ03; AZ04; AZ05; AZ06; AZ07; AZ08; AZ09; AZ10; AZ11; AZ12; AZ13; AZ14; AZ15; AZ16; AZ17; AZ18; AZ19; AZ20; BUFURALOL; CHEMICAL COMPOUND; DEXTROMETHORPHAN; DICLOFENAC; DILTIAZEM; IMIPRAMINE; MIDAZOLAM; PHENACETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MAXIMUM RATE OF THE REACTION; METABOLIC INTRINSIC CLEARANCE; METABOLISM; MICHAELIS CONSTANT; MULTIPLE DEPLETION CURVES METHOD; OPTIMAL DESIGN APPROACH; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MICROSOMES, LIVER; RESEARCH DESIGN; TANDEM MASS SPECTROMETRY;

EID: 84869118121     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047373     Document Type: Article

References (29)

1. Di L, Kerns EH, Gao N, Li SQ, Huang Y, Bourassa JL, and Huryn DM (2004) Experimental design on single-time-point high-throughput microsomal stability assay. J Pharm Sci 93:1537-1544.
2. Di L, Kerns EH, Hong Y, Kleintop TA, McConnell OJ, and Huryn DM (2003) Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomol Screen 8:453-462.
3. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
4. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmacol Res 22:103-112.
5. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1125.
6. Kakkar T, Pak Y, and Mayersohn M (2000) Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. J Pharmacol Exp Ther 293:861-869.
7. Koyama E, Chiba K, Tani M, and Ishizaki T (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199-1210.
8. Leemann T, Transon C, and Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
9. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, and Leroux JP (1993) Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827-832.
10. Li XQ, Björkman A, Andersson TB, Ridderström M, and Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399-407.
11. Masimirembwa CM, Thompson R, and Andersson TB (2001) In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 4:245-263.
12. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
13. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
14. Poirier A, Funk C, Scherrmann JM, and Lavé T (2009) Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 6:1716-1733.
15. Ring BJ, Binkley SN, Vandenbranden M, and Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
16. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
17. Saraswat LD, Caserta KA, Laws K, Wei D, Jones SS, and Adedoyin A (2003) A high-throughput method for enzyme kinetic studies. J Biomol Screen 8:544-554.
18. Sjögren E, Lennernäs H, Andersson TB, Gråsjö J, and Bredberg U (2009) The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab Dispos 37:47-58.
19. Sjögren E, Nyberg J, Magnusson MO, Lennernäs H, Hooker A, and Bredberg U (2011) Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment. Drug Metab Dispos 39:858-863.
20. Sutton D, Butler AM, Nadin L, and Murray M (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 282:294-300.
21. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
22. Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, and Lennernäs H (2011) Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 43:89-98.
23. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
24. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568-577.
25. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 31:232-241.
26. Youdim K and Dodia R (2010) Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants. Xenobiotica 40:235-244.
27. Zhang T, Zhu Y, and Gunaratna C (2002) Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatographyelectrospray ionization-ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 780:371-379.
28. Zhao P, Lee CA, and Kunze KL (2007) Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 35:704-712.
29. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, et al. (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267.